Recent advances in etiology and treatment of von Hippel-Lindau Disease (VHLD)
Shabnam Pirestani, Emmanuelle Nicolas, Robert L Broadrup, Margie L Clapper, Erica Golemis · 2026
Read Recent advances in etiology and treatment of von Hippel-Lindau Disease (VHLD) by Shabnam Pirestani, Emmanuelle Nicolas, Robert L Broadrup, Margie L Clapper, Erica Golemis (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13473127.txt.
Description
Shabnam Pirestani and co-authors review recent progress on von Hippel-Lindau disease, a rare inherited condition that predisposes people to cancers in many organs. About one person in thirty-five thousand carries the faulty gene. Tumors of the kidney, pancreas, and brain blood vessels are common, alongside benign cysts. Risk for each depends on where the gene is damaged.
The faulty protein normally tags a key oxygen-sensing factor for disposal. When tagging fails, the factor piles up and switches on growth programs. A drug blocking that factor's signaling, belzutifan, has become a leading treatment for kidney tumors in these patients. The review also covers the protein's lesser-known jobs, from cell skeleton upkeep to surface hair-like structures, whose loss may add to the disease. Prevention and early interception close the survey.
Catalog record
| CREATOR | Shabnam Pirestani, Emmanuelle Nicolas, Robert L Broadrup, Margie L Clapper, Erica Golemis |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |